September 2, 2026 – VivoSim Labs, Inc. (NASDAQ: VIVS) is expanding the potential commercial reach of its NAMkind™ drug toxicology platform, announcing plans to develop a rat liver model that would complement its existing 3D human liver model and help pharmaceutical companies distinguish animal-specific toxicity from risks that may translate to humans.
The development could broaden VivoSim’s role in pharmaceutical R&D by creating a cross-species toxicology capability that works alongside existing animal-testing workflows. VivoSim’s human liver model is designed to identify potential human toxicity that may not appear in animal studies, while the planned rat model would help determine whether adverse findings observed in rats may be species-specific rather than predictive of human risk.
For pharmaceutical companies, that additional information could help determine whether drug candidates should advance, be modified, further investigated or discontinued before substantially more development capital is committed.
Alongside VivoSim Labs, Inc (NASDAQ: VIVS) investors are also watching several actively traded stocks, including Vivakor, Inc (NASDAQ: VIVK), Gelteq (NASDAQ: GELS), Viomi Technology Co (NASDAQ: VIOT) and Farmmi Inc (NASDAQ: FAMI) as small-cap micro-cap and emerging growth stocks continue attracting market attention.
VivoSim plans to validate the rat model using compounds with known differences between rat and human liver toxicity. If successfully validated and commercially adopted, the paired platform could expand the use of NAMkind™ across preclinical toxicology, candidate selection and investigative toxicology.
The strategy also strengthens VivoSim’s broader positioning around 3D human tissue models and AI-powered predictive toxicology. The company has previously reported approximately 91% predictive accuracy for liver toxicity, while its intestinal platform and predictive analytics have demonstrated strong performance identifying drug-induced gastrointestinal toxicity.
The expansion comes as the FDA continues advancing New Approach Methodologies (NAMs) and human-relevant testing approaches intended to reduce reliance on traditional animal studies. While this regulatory movement does not represent FDA endorsement of VivoSim specifically, it could provide a favorable industry backdrop for validated human-based toxicology technologies.
For VIVS investors, the planned cross-species capability could expand the commercial utility and addressable applications of NAMkind™. VivoSim has reiterated expectations for 500%+ fiscal 2027 revenue growth from its NAM-based contract research business and recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested drug program.
The developing investment thesis is increasingly straightforward: VivoSim is positioning NAMkind™ as a decision-support platform that could help pharmaceutical companies distinguish animal-specific toxicity from human risk and make better drug-development decisions earlier.
About VivoSim Labs
VivoSim Labs, Inc. (NASDAQ: VIVS) is a pharmaceutical and biotechnology services company providing NAMkind™ 3D human liver and intestinal tissue models and predictive toxicology technologies designed to support drug-development decisions using New Approach Methodologies (NAMs).
About The Street Reports
The Street Reports (TSR) a financial media platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com
